REMS Abuse Website: Celgene, Actelion Top List Of Suspected 'Gamers'
Other sponsors could be using tactics other than REMS abuse to game the system, US FDA Commissioner Scott Gottlieb says.
You may also be interested in...
Teva has bolstered its oncology offering in the US by moving first on one of the largest small-molecule opportunities in the US: Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) to treat multiple myeloma.
As generics of Gilead’s Truvada combination antiretroviral reach the US market, their manufacturers will no longer have to provide risk-mitigation education.
Four different firms have simultaneously received FDA approval for ambrisentan generics of Gilead’s Letairis. But different safety programs suggest Zydus Pharma may be taking a different commercial approach to the other three generics firms.